In a study published in Cancer Medicine, researchers found that in a large cohort of patients with chronic lymphocytic leukemia (CLL) receiving commercial ibrutinib (Imbruvica), initial ibrutinib dose and dose modification during therapy did not appear to impact event-free survival (EFS) or overall survival (OS).
These findings highlighted the challenges associated with continuous oral therapy with ibrutinib in patients with CLL. The results also confirmed observations from other “real-world” analyses that more patients stop ibrutinib due to toxicity rather than due to progression of disease.
“This latter finding has major implications for clinical trial design where combination therapies with fixed duration of treatment that achieve deep remission may be more desirable than chronic long-term treatment,” the authors wrote.
Conducting a retrospective study of patients…